Ravian Life Sciences


Conjug8 Corp


Concise Prescribing Info
Management of schizophrenia. Treatment of moderate to severe mania associated w/ bipolar disorder.
Dosage/Direction for Use
Schizophrenia Adult Initially 5-10 mg once daily w/ a target dose of 10 mg/day w/in several days. Further adjust dose in increments/decrements of 5 mg once daily if necessary. Maintenance dose: 10-20 mg/day. Adolescent Initially 2.5 mg or 5 mg w/ a target dose of 10 mg/day. Adjust dose in increments/decrements of 2.5 mg or 5 mg if necessary. Bipolar I disorder (manic or mixed episodes) Adult Monotherapy: 10-15 mg once daily. Adjust dose in increments/decrements of 5 mg once daily if necessary. Adjunctive treatment: 10 mg once daily w/ lithium or valproate. Adolescent Initially 2.5 mg or 5 mg w/ a target dose of 10 mg/day.
May be taken with or without food.
Special Precautions
Increased risk of death in elderly patients w/ dementia. Not for the treatment of patients w/ dementia-related psychosis & Alzheimer's disease. Possibility of suicide attempt. Neuroleptic malignant syndrome. Hyperlipidemia. Wt gain. Risk of developing tardive dyskinesia. Patients w/ known CV disease (history of MI or ischemia, heart failure or conduction abnormalities), cerebrovascular disease & conditions which predispose patients to hypotension. History of seizures or conditions that potentially lower seizure threshold eg, Alzheimer's dementia. Elevation in core body temp. Hyperprolactinemia. Not intended for use in ped patients who exhibits symptoms secondary to environmental factors &/or other primary psychiatric disorders. Concomitant administration of IM olanzapine w/ parenteral benzodiazepine. Monitor regularly for worsening of glucose control; symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, & weakness. Perform fasting blood glucose testing & lipid profile at the beginning of, & periodically during treatment. Potential for cognitive & motor impairment. Pregnancy. Do not breast-feed. Childn <13 yr.
Adverse Reactions
Drowsiness, dizziness, restlessness, unusual behavior, depression, difficulty falling asleep or staying asleep, weakness, difficulty walking, constipation, wt gain, dry mouth, arms, legs, back, or joints pain, breast enlargement or discharge, late or missed menstrual periods, decreased sexual ability.
Drug Interactions
Potentiated orthostatic hypotension w/ diazepam & alcohol (ie, ethanol). Increased clearance w/ carbamazepine. Decreased clearance w/ fluvoxamine. Small increase in max conc & small decrease in clearance w/ fluoxetine. May increase clearance w/ rifampin. Reduced Cmax & AUC w/ charcoal. May enhance effects of antihypertensive agents. May antagonize the effects of levodopa & dopamine. Centrally acting drugs & alcohol.
MIMS Class
ATC Classification
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics
Zenia-10 orodispersible tab 10 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in